Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation

Recruiting now · Not applicable

Conditions studied: Hepatic Cancer, Hepatic Resection

In brief

The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery/therapy.

Key facts

Study ID

NCT06718153

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

100

Starts

2024-10-23

Expected to finish

2025-06-01

Last updated by the study team

2024-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Patients resected for HCC
• Availability of NGS data
• Availability of paraffin material for immunohistochemistry investigations

You may not qualify if…

• None

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.